AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Ironwood Pharmaceuticals to Present at Upcoming March Investor Conferences

February 25, 2020 GMT

BOSTON--(BUSINESS WIRE)--Feb 25, 2020--

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present corporate updates at two upcoming investor conferences in March:

  • Cowen and Company 40 th Annual Healthcare Conference on Tuesday, March 3, 2020 at 8:00 a.m. ET at The Boston Marriott Copley Place in Boston.
  • Barclays Global Healthcare Conference on Thursday, March 12, 2020 at 10:45 a.m. ET at the Loews Miami Beach Hotel in Miami.

A live webcast of Ironwood’s presentations will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. To access the webcasts, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Ironwood’s website for 14 days following the conference.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. We discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).

We are also advancing two late-stage, first-in-category GI product candidates: IW-3718 is a gastric retentive formulation of a bile acid sequestrant being developed for the potential treatment of refractory gastroesophageal reflux disease, and MD-7246 is a delayed-release formulation of linaclotide that is being evaluated as an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated certain GI diseases.

Ironwood was founded in 1998 and is headquartered in Boston, Mass. For more information, please visit our website at www.ironwoodpharma.com or www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both these locations.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200225005727/en/

CONTACT: Investor and Media Relations

Meredith Kaya, 617-374-5082

Vice President, Strategy, Investor Relations and Corporate Communications

mkaya@ironwoodpharma.com

KEYWORD: FLORIDA MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH

SOURCE: Ironwood Pharmaceuticals, Inc.

Copyright Business Wire 2020.

PUB: 02/25/2020 04:05 PM/DISC: 02/25/2020 04:05 PM

http://www.businesswire.com/news/home/20200225005727/en